Share on LinkedInShare on LinkedIn

ARTICLE · 21 MAY 2012

Ontario Denies Certification In Proposed National Class Action On Anti-Psychotic Medicine

McCarthy Tétrault
McCarthy Tétrault
Contributor
McCarthy Tétrault

McCarthy Tétrault

McCarthy Tétrault LLP provides a broad range of legal services, delivering strategic and...

View firm profile
Explore more from McCarthy Tétrault

In a landmark ruling released on May 7, Madam Justice Carolyn Horkins of the Ontario Superior Court denied certification of a proposed national class action involving the atypical anti-psychotic medicine, Seroquel®.

CanadaLitigation, Mediation & Arbitration

In a landmark ruling released on May 7, Madam Justice Carolyn Horkins of the Ontario Superior Court denied certification of a proposed national class action involving the atypical anti-psychotic medicine, Seroquel®. In Martin v. AstraZeneca Pharmaceuticals Plc, the plaintiffs made a broad range of allegations against three AstraZeneca companies in relation to the design, manufacture, marketing and sale of Seroquel®, a leading medicine used to treat schizophrenia and bipolar disorder. The principal claims were that Seroquel® causes serious health risks that were not adequately warned of in the product monograph approved by Health Canada. The plaintiffs also alleged that the defendants conspired to conceal safety information from Health Canada and to promote the medicine for off-label, unapproved uses. McCarthy Tétrault acts for AstraZeneca in the proceeding.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from